Obstructive Sleep Apnea and Cerebral Small Vessel disease in Community-based Older People: An ASPREE Imaging Substudy.

IF 5.6 2区医学 Q1 Medicine

Sleep Pub Date : 2024-09-20 DOI:10.1093/sleep/zsae204

Stephanie A Ward, Elsdon Storey, Matthew T Naughton, Rory Wolfe, Garun S Hamilton, Meng Law, Ryo Kawasaki, Walter P Abhayaratna, Katherine L Webb, Fergal J O'Donoghue, Danijela Gasevic, Nigel P Stocks, Ruth E Trevaks, Liubov D Robman, Scott Kolbe, Sharyn M Fitzgerald, Suzanne G Orchard, Tien Wong, John McNeil, Christopher M Reid, Ben Sinclair, Robyn L Woods

{"title":"Obstructive Sleep Apnea and Cerebral Small Vessel disease in Community-based Older People: An ASPREE Imaging Substudy.","authors":"Stephanie A Ward, Elsdon Storey, Matthew T Naughton, Rory Wolfe, Garun S Hamilton, Meng Law, Ryo Kawasaki, Walter P Abhayaratna, Katherine L Webb, Fergal J O'Donoghue, Danijela Gasevic, Nigel P Stocks, Ruth E Trevaks, Liubov D Robman, Scott Kolbe, Sharyn M Fitzgerald, Suzanne G Orchard, Tien Wong, John McNeil, Christopher M Reid, Ben Sinclair, Robyn L Woods","doi":"10.1093/sleep/zsae204","DOIUrl":null,"url":null,"abstract":"Study objectives: Obstructive sleep apnea (OSA) may increase risk of dementia. A potential pathway for this risk is through cerebral small vessel disease (CSVD). In the context of an existing randomized trial of aspirin for primary prevention, we aimed to investigate OSA's impact on CSVD imaging measures and explore whether aspirin effects these measures over 3 years that differ in the presence or absence of OSA.Methods: A sub-study of the ASPirin in Reducing Events in the Elderly randomized placebo-controlled trial of low-dose aspirin. Community-dwelling participants aged 70 years and above, without cognitive impairment, cardiovascular disease or known OSA completed an unattended limited-channel sleep study that calculated the oxygen desaturation index and apnea-hypopnea index. At baseline and 3 years later, volumes of white matter hyperintensities (WMH) and silent brain infarctions (SBI) were measured on 1.5 Tesla brain magnetic resonance imaging, and retinal vessel calibers were calculated from retinal vascular imaging.Results: Mild and moderate/severe OSA was detected in 48.9% and 29.9%, respectively, of the 311 participants, who had a mean age of 73.7 years (SD 3.4 years), 38.6% female. OSA of any severity did not associate with WMH volumes, SBI, nor with retinal vessel calibers at baseline, nor with change in these measures in the 277 participants with repeated measures acquired after 3 years. OSA of any severity did not interact with aspirin on change in these measures over 3 years.Conclusion: In healthy older adults undiagnosed OSA was not associated with retinal vascular calibers and neuroimaging measures of CSVD.","PeriodicalId":22018,"journal":{"name":"Sleep","volume":null,"pages":null},"PeriodicalIF":5.6000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sleep/zsae204","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Study objectives: Obstructive sleep apnea (OSA) may increase risk of dementia. A potential pathway for this risk is through cerebral small vessel disease (CSVD). In the context of an existing randomized trial of aspirin for primary prevention, we aimed to investigate OSA's impact on CSVD imaging measures and explore whether aspirin effects these measures over 3 years that differ in the presence or absence of OSA.

Methods: A sub-study of the ASPirin in Reducing Events in the Elderly randomized placebo-controlled trial of low-dose aspirin. Community-dwelling participants aged 70 years and above, without cognitive impairment, cardiovascular disease or known OSA completed an unattended limited-channel sleep study that calculated the oxygen desaturation index and apnea-hypopnea index. At baseline and 3 years later, volumes of white matter hyperintensities (WMH) and silent brain infarctions (SBI) were measured on 1.5 Tesla brain magnetic resonance imaging, and retinal vessel calibers were calculated from retinal vascular imaging.

Results: Mild and moderate/severe OSA was detected in 48.9% and 29.9%, respectively, of the 311 participants, who had a mean age of 73.7 years (SD 3.4 years), 38.6% female. OSA of any severity did not associate with WMH volumes, SBI, nor with retinal vessel calibers at baseline, nor with change in these measures in the 277 participants with repeated measures acquired after 3 years. OSA of any severity did not interact with aspirin on change in these measures over 3 years.

Conclusion: In healthy older adults undiagnosed OSA was not associated with retinal vascular calibers and neuroimaging measures of CSVD.

查看原文本刊更多论文

社区老年人的阻塞性睡眠呼吸暂停和脑小血管疾病：ASPREE 成像子研究。

研究目的：阻塞性睡眠呼吸暂停（OSA）可能会增加痴呆症的风险。这种风险的一个潜在途径是脑小血管疾病（CSVD）。在现有的阿司匹林一级预防随机试验的背景下，我们旨在调查 OSA 对 CSVD 影像学指标的影响，并探讨阿司匹林是否会在 3 年内影响这些指标，而这些指标在有无 OSA 的情况下会有所不同：低剂量阿司匹林随机安慰剂对照试验 "ASPirin in Reducing Events in the Elderly "的一项子研究。年龄在 70 岁及以上、无认知障碍、心血管疾病或已知 OSA 的社区居民完成了一项无人值守的有限通道睡眠研究，该研究计算了氧饱和度指数和呼吸暂停-低通气指数。基线和3年后，1.5特斯拉脑磁共振成像测量了白质高密度（WMH）和无声脑梗塞（SBI）的体积，视网膜血管成像计算了视网膜血管口径：311名参与者中分别有48.9%和29.9%的人被检测出患有轻度和中度/重度OSA，他们的平均年龄为73.7岁（标准差3.4岁），其中38.6%为女性。任何严重程度的 OSA 均与基线时的 WMH 体积、SBI 或视网膜血管口径无关，也与 3 年后获得重复测量值的 277 名参与者的这些测量值的变化无关。任何严重程度的OSA与阿司匹林在3年内对这些指标的变化没有相互作用：结论：在健康的老年人中，未确诊的 OSA 与 CSVD 的视网膜血管口径和神经影像测量结果无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Sleep Medicine-Neurology (clinical)

CiteScore

8.70

自引率

10.70%

发文量

期刊介绍： SLEEP® publishes findings from studies conducted at any level of analysis, including: Genes Molecules Cells Physiology Neural systems and circuits Behavior and cognition Self-report SLEEP® publishes articles that use a wide variety of scientific approaches and address a broad range of topics. These may include, but are not limited to: Basic and neuroscience studies of sleep and circadian mechanisms In vitro and animal models of sleep, circadian rhythms, and human disorders Pre-clinical human investigations, including the measurement and manipulation of sleep and circadian rhythms Studies in clinical or population samples. These may address factors influencing sleep and circadian rhythms (e.g., development and aging, and social and environmental influences) and relationships between sleep, circadian rhythms, health, and disease Clinical trials, epidemiology studies, implementation, and dissemination research.